German Parkinson Study Group (GPS) Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2003
NCT00146809
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

minocycline (minocin) (1 trial)

Drugs in Phase 2 Trials (2)

nicotine (nicorette) (1 trial)

vitamin q (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Multiple System Atrophy (Phase 3)

Paralysis (Phase 2)

Parkinson Disease (Phase 2)

Shy-Drager Syndrome (Phase 3)

Supranuclear Palsy, Progressive (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3